ABT-737, a Bcl-2 selective inhibitor, and chloroquine synergistically kill renal cancer cells

Oncology Research

Volumn 24, Issue 1, 2016, Pages 65-72

  Yin, Pei ^a   Jia, Jinpeng ^a   Li, Jijun ^a   Song, Yan ^a   Zhang, Yiyan ^a   Chen, Fengkun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ABT 737; Apoptosis; Chloroquine; Combination treatment; Renal cancer

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CHLOROQUINE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; REACTIVE OXYGEN METABOLITE; TROLOX C; 2-(3-CHLOROPROPIONYLAMINO)-1,3,4-THIADIAZOLE-5-SULFONAMIDE; ABT-737; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BENZOYLCARBONYL-ASPARTYL-GLUTAMYL-VALYL-ASPARTYL-FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; BIPHENYL DERIVATIVE; LEUCINE; NITROPHENOL; OLIGOPEPTIDE; PEPTIDE CHLOROMETHYL KETONE; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; SULFONAMIDE; THIADIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; THERAPEUTIC INDEX; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; DRUG EFFECTS; KIDNEY NEOPLASMS; METABOLISM; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; CARCINOMA, RENAL CELL; CELL DEATH; CELL LINE, TUMOR; CHLOROQUINE; DRUG SYNERGISM; HUMANS; KIDNEY NEOPLASMS; LEUCINE; NITROPHENOLS; OLIGOPEPTIDES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; THIADIAZOLES;

EID: 84970939917     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14587366983838     Document Type: Article

References (32)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 61:69-90; 2011.
2. Gupta, K.; Miller, J. D.; Li, J. Z.; Russell, M. W.; Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat. Rev. 34:193-205; 2008.
3. Skarzynski, M.; Niemann, C. U.; Lee, Y. S.; Martyr, S.; Maric, I.; Salem, D.; Stetler-Stevenson, M.; Marti, G. E.; Calvo, K. R.; Yuan, C.; Valdez, J.; Soto, S.; Farooqui, M. Z.; Herman, S. E.; Wiestner, A. Interactions between ibrutinib and anti-CD20 antibodies: Competing effects on the outcome of combination therapy. Clin. Cancer Res. 22:86-95; 2016.
4. Inoue, S.; Salah-Eldin, A. E.; Omoteyama, K. Apoptosis and anticancer drug resistance. Human Cell 14:211-221; 2001.
5. Cosentino, K.; Garcia-Saez, A. J. Mitochondrial alterations in apoptosis. Chem. Phys. Lipids 181:62-75; 2014.
6. Elkholi, R.; Renault, T. T.; Serasinghe, M. N.; Chipuk, J. E. Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy? Cancer Metab. 2:16; 2014.
7. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27:6434-6451; 2008.
8. Boya, P.; Gonzalez-Polo, R. A.; Poncet, D.; Andreau, K.; Vieira, H. L.; Roumier, T.; Perfettini, J. L.; Kroemer, G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22:3927-3936; 2003.
9. Blomgran, R.; Zheng, L.; Stendahl, O. Cathepsin-cleaved Bid promotes apoptosis in human neutrophils via oxidative stress-induced lysosomal membrane permeabilization. J. Leukoc. Biol. 81:1213-1223; 2007.
10. Mnich, K.; Carleton, L. A.; Kavanagh, E. T.; Doyle, K. M.; Samali, A.; Gorman, A. M. Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent manner. Cell Death Dis. 5:e1202; 2014.
11. Sasi, N.; Hwang, M.; Jaboin, J.; Csiki, I.; Lu, B. Regulated cell death pathways: New twists in modulation of BCL2 family function. Mol. Cancer Ther. 8:1421-1429; 2009.
12. Kagedal, K.; Johansson, A. C.; Johansson, U.; Heimlich, G.; Roberg, K.; Wang, N. S.; Jurgensmeier, J. M.; Ollinger, K. Lysosomal membrane permeabilization during apoptosis- Involvement of Bax? Int. J. Exp. Pathol. 86:309-321; 2005.
13. Oberle, C.; Huai, J.; Reinheckel, T.; Tacke, M.; Rassner, M.; Ekert, P. G.; Buellesbach, J.; Borner, C. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bakdependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell Death Differ. 17:1167-1178; 2010.
14. Kline, M. P.; Rajkumar, S. V.; Timm, M. M.; Kimlinger, T. K.; Haug, J. L.; Lust, J. A.; Greipp, P. R.; Kumar, S. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21:1549-1560; 2007.
15. Fan, C.; Wang, W.; Zhao, B.; Zhang, S.; Miao, J. Chloroquine inhibits cell growth and induces cell death in A549 lung cancer cells. Bioorg. Med. Chem. 14:3218-3222; 2006.
16. Zhang, J.; Wang, X.; Cui, W.; Wang, W.; Zhang, H.; Liu, L.; Zhang, Z.; Li, Z.; Ying, G.; Zhang, N.; Li, B. Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage. Nat. Commun. 4:2157; 2013.
17. Cui, Y.; Yang, S.; Fu, X.; Feng, J.; Xu, S.; Ying, G. High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer. Int. J. Mol. Sci. 16:363- 377; 2015.
18. Chen, Z. X.; Pervaiz, S. Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ. 17:408-420; 2010.
19. Kurz, T.; Terman, A.; Gustafsson, B.; Brunk, U. T. Lysosomes and oxidative stress in aging and apoptosis. Biochim. Biophys. Acta 1780:1291-1303; 2008.
20. Coppin, C.; Kollmannsberger, C.; Le, L.; Porzsolt, F.; Wilt, T. J. Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials. BJU Int. 108:1556-1563; 2011.
21. Zall, H.; Weber, A.; Besch, R.; Zantl, N.; Hacker, G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol. Cancer 9:164; 2010.
22. Woo, S. M.; Min, K. J.; Seo, B. R.; Nam, J. O.; Choi, K. S.; Yoo, Y. H.; Kwon, T. K. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression. Cell Death Dis. 5:e1514; 2014.
23. Wiesner, J.; Ortmann, R.; Jomaa, H.; Schlitzer, M. New antimalarial drugs. Angew. Chem. Int. Ed. Engl. 42:5274- 5293; 2003.
24. Njaria, P. M.; Okombo, J.; Njuguna, N. M.; Chibale, K. Chloroquine-containing compounds: A patent review (2010-2014). Expert Opin. Ther. Pat. 25:1003-1024; 2015.
25. Tang, M. C.; Wu, M. Y.; Hwang, M. H.; Chang, Y. T.; Huang, H. J.; Lin, A. M.; Yang, J. C. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One 10:e0119135; 2015.
26. Kimura, T.; Shirakawa, R.; Yaoita, N.; Hayashi, T.; Nagano, K.; Horiuchi, H. The antimalarial drugs chloroquine and primaquine inhibit pyridoxal kinase, an essential enzyme for vitamin B6 production. FEBS Lett. 588:3673-3676; 2014.
27. Liu, F.; Shang, Y.; Chen, S. Z. Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro. Acta Pharmacol. Sin. 35:645-652; 2014.
28. Zinn, R. L.; Gardner, E. E.; Dobromilskaya, I.; Murphy, S.; Marchionni, L.; Hann, C. L.; Rudin, C. M. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. Mol. Cancer 12:16; 2013.
29. Kimura, T.; Takabatake, Y.; Takahashi, A.; Isaka, Y. Chloroquine in cancer therapy: A double-edged sword of autophagy. Cancer Res. 73:3-7; 2013.
30. Yang, Y.; Karakhanova, S.; Hartwig, W.; D'Haese, J. G.; Philippov, P. P.; Werner, J.; Bazhin, A. V. Mitochondria and mitochondrial ROS in cancer: Novel targets for anticancer therapy. J. Cell. Physiol.; 2016. doi: 10.1002/jcp.25349; 2016 (Epub ahead of print).
31. Takamura, A.; Komatsu, M.; Hara, T.; Sakamoto, A.; Kishi, C.; Waguri, S.; Eishi, Y.; Hino, O.; Tanaka, K.; Mizushima, N. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25:795-800; 2011.
32. Takahashi, A.; Kimura, T.; Takabatake, Y.; Namba, T.; Kaimori, J.; Kitamura, H.; Matsui, I.; Niimura, F.; Matsusaka, T.; Fujita, N.; Yoshimori, T.; Isaka, Y.; Rakugi, H. Autophagy guards against cisplatin-induced acute kidney injury. Am. J. Pathol. 180:517-525; 2012.